US flu hospitalizations increased nearly 30% in the week before Thanksgiving; HHS proposed a rule to align 42 CFR Part 2 privacy protections with existing law to protect patients with substance abuse disorder; New York State saw a decline in opioid prescriptions during the first month of COVID-19 lockdowns.
Flu hospitalizations increased nearly 30% in a week in the United States, with more than 11,200 patients hospitalized during the week of November 13 compared with around 8700 patients the week prior, CNBC reported. Flu has hit the United States especially hard this season, with around 11 in every 100,000 individuals being hospitalized since early October, which is the highest level in a decade. According to CDC data, there have been more than 6.2 million flu cases, 53,000 hospitalizations, and 2900 deaths this season. Experts are concerned hospitalizations will surge more around the winter holidays, especially as the H3N2 flu variant—which is more severe for older adults—is currently the dominant variant.
HHS proposed a rule Monday aimed at aligning 42 CFR Part 2 privacy protections with the Health Insurance Portability and Accountability Act (HIPAA) to protect patients with substance abuse disorder, Axios reported. To facilitate the sharing of patient information between providers, the rule requires one-time patient consent for disclosure of treatment, allowing HIPAA-covered entities to access certain patient records. The rule will also grant patients the right to know when and where their information was disclosed and request restrictions on what information providers can access, as well as prohibit courts from using Part 2 records against the patient in civil or criminal proceedings. Behavioral health advocates called this proposal a critical step in managing the opioid crisis.
Early New York State COVID-19 lockdowns were associated with a decline in opioid prescriptions as well as steady prescription rates for medications for opioid use disorder (MOUD), Columbia Mailman School of Public Health reported. According to a study published in Addiction, the total weekly morphine milligram equivalents (MME) per day per zip code of dispensed non-MOUD opioids steadily declined between March 21, 2020, and April 17, 2020. Mean weekly total MME/day dispensed during this first month of COVID-19 lockdowns was 17.07% lower compared with the 4 weeks prior to March 21, 2020, which the authors said was almost entirely due to a drop in MME/day dispensed for prescriptions of 7 days or shorter. The study authors also noted that policy initiatives by the Substance Abuse and Mental Health Services Administration were likely the reason emergency orders did not affect access to MOUD.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More